<DOC>
	<DOCNO>NCT00091260</DOCNO>
	<brief_summary>RATIONALE : Drugs CC-5013 dexamethasone may effective treat primary systemic amyloidosis . PURPOSE : This phase II trial study CC-5013 see well work without dexamethasone treat patient primary systemic amyloidosis .</brief_summary>
	<brief_title>CC-5013 With Without Dexamethasone Treating Patients With Primary Systemic Amyloidosis</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine tolerability CC-5013 patient primary systemic ( AL ) amyloidosis . - Determine objective hematologic response rate patient treat drug . - Determine amyloid organ disease response patient treated drug . Secondary - Determine hematologic amyloid organ disease response patient achieve response CC-5013 alone subsequently treat CC-5013 dexamethasone . - Determine toxicity CC-5013 combination dexamethasone patient . OUTLINE : Patients receive oral CC-5013 daily day 1-21 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients achieve hematologic response continue receive CC-5013 also receive oral dexamethasone twice daily day 1-4 , 9-12 , 17-20 every 28-day course 6 course combination therapy . Patients maintain hematologic response 6 course combination therapy may receive CC-5013 alone absence disease progression unacceptable toxicity . Patients achieve hematologic response initiation dexamethasone remove study . Patients follow annually . PROJECTED ACCRUAL : A total 15-25 patient accrue study within 5-12.5 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary systemic ( AL ) amyloidosis Tissue amyloid deposit positive fat aspirate Meets 1 follow criterion AL type disease : Serum urine monoclonal protein immunofixation electrophoresis Plasmacytosis bone marrow monoclonal staining kappa lambdalight chain isotype PATIENT CHARACTERISTICS : Age 18 Performance status SWOG 02 Life expectancy Not specify Hematopoietic White blood count &gt; 3,000/mm^3 Hemoglobin &gt; 8 g/dL Platelet count &gt; 100,000/mm^3 Absolute neutrophil count &gt; 1,000/mm^3 Hepatic Bilirubin ≤ 2 time upper limit normal ( ULN ) aspartate aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) ≤ 2 time ULN PRIOR CONCURRENT THERAPY : Biologic therapy Prior thalidomide AL amyloidosis allow Chemotherapy More 4 week since prior cytotoxic chemotherapy Endocrine therapy Prior steroid AL amyloidosis allow Radiotherapy More 4 week since prior radiotherapy Surgery Prior surgery allow Other Recovered prior therapy No secondary familial amyloidosis No multiple myeloma , define ≥ 30 % plasma cell bone marrow biopsy specimen OR lytic bone lesions No prior CC5013 Renal No dialysis Cardiovascular No symptomatic cardiac arrhythmia No oxygendependent restrictive cardiomyopathy Other No untreated uncontrolled infection No malignancy except basal cell skin cancer carcinoma situ cervix breast No serious medical illness would preclude study participation No history hypersensitivity reaction thalidomide HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>primary systemic amyloidosis</keyword>
</DOC>